PwPepwise

Cerebrolysin

Brain & Focus

Porcine brain-derived peptide mixture

Cerebrolysin is a standardized mixture of low-molecular-weight peptides and free amino acids derived from purified pig brain proteins.

§01Summary

Cerebrolysin is a standardized mixture of low-molecular-weight peptides and free amino acids derived from purified pig brain proteins, administered intravenously to support brain cell survival, repair, and recovery. It is thought to act similarly to the brain's own growth factors, helping neurons withstand injury and potentially promoting the formation of new connections after damage. In stroke recovery, Cerebrolysin improves neurological function scores compared to placebo, with a number-needed-to-treat of approximately 7-8 patients to achieve a clinically meaningful improvement5,6. In Alzheimer's disease, it improves global clinical functioning compared to placebo across multiple trials3,7,10,11, and in vascular dementia, it has been reported to produce large improvements in both cognitive and functional outcomes4. The drug also appears to benefit motor function recovery after stroke when combined with rehabilitation6,12, and may support recovery from traumatic brain injury14 and post-stroke aphasia18. Cerebrolysin is widely used in Russia, Eastern Europe, China, and other post-Soviet countries, though it is not approved by the FDA or EMA. Its intravenous-only route of administration is a practical consideration for patients and clinicians alike1,10.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Cerebrolysin is a parenterally administered neuropeptide preparation derived from standardized enzymatic hydrolysis of purified porcine cortical brain tissue. The final product consists of approximately 25% low-molecular-weight biologically active peptide fragments (molecular weight below 10,000 Da) and 75% free amino acids, produced under controlled manufacturing conditions to ensure batch consistency. Because the peptide components are small enough to cross the blood-brain barrier, they are thought to exert direct central nervous system effects following systemic intravenous administration10.

The proposed primary mechanism of action involves neurotrophic factor mimicry. Cerebrolysin's peptide constituents are believed to interact with high-affinity neurotrophin receptors — including TrkA, TrkB, and TrkC — and with p75 neurotrophin receptor (p75NTR) signaling pathways, mimicking the activity of endogenous neurotrophic factors such as nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and ciliary neurotrophic factor (CNTF). This receptor engagement activates downstream survival cascades including the PI3K/Akt and MAPK/ERK pathways, promoting neuronal survival, axonal sprouting, synaptic plasticity, and inhibition of apoptotic signaling in injured neural tissue10,11.

Secondary mechanistic effects include modulation of neuronal energy metabolism — specifically enhancement of aerobic glucose utilization and mitochondrial function under ischemic or degenerative stress — as well as neuromodulatory effects on cholinergic, glutamatergic, and dopaminergic transmission. The preparation has been proposed to reduce excitotoxic neuronal death by attenuating excess glutamate-mediated calcium influx, and to inhibit calpain-mediated cytoskeletal degradation in the post-ischemic penumbra10. In Alzheimer's disease models, Cerebrolysin has been associated with reduced amyloid precursor protein processing and tau hyperphosphorylation, consistent with potential disease-modifying activity beyond symptomatic neurotransmitter augmentation11.

Neuroimaging evidence from a clinical RCT provides biological correlates for these mechanisms: Cerebrolysin administered alongside rehabilitation was associated with restriction of corticospinal tract diffusivity increments on diffusion tensor imaging (DTI) and recovery of sensorimotor connectivity on resting-state fMRI, suggesting preserved white matter integrity and restored functional network organization13. The durable clinical benefits observed in Alzheimer's disease trials — persisting 2–3 months after treatment cessation11,17 — are consistent with neuroplastic or disease-modifying mechanisms rather than purely symptomatic pharmacological effects. Pharmacokinetically, Cerebrolysin is administered intravenously due to the susceptibility of its peptide components to gastrointestinal proteolysis; no oral bioavailability data are currently established for the clinical preparation.

§04Evidence & efficacy

Evidence base
320Studies
131Human
65Animal

Cerebrolysin demonstrates consistent improvements in neurological function after acute ischemic stroke across multiple trials and meta-analyses. A pre-planned meta-analysis of nine RCTs (N=1,879) found significant superiority over placebo on the NIH Stroke Scale at day 30 (Mann-Whitney effect size 0.60, P<0.0001), with a number-needed-to-treat of 7.7 for clinically meaningful improvement5. Motor function recovery, measured by the Action Research Arm Test at day 90, also significantly favored Cerebrolysin in pooled CARS data (MW 0.62, P<0.0001, NNT 7.1)6,12. A dedicated RCT of Cerebrolysin combined with speech and language therapy showed significantly greater Western Aphasia Battery score improvements at day 90 compared to placebo plus therapy18.

In Alzheimer's disease, Cerebrolysin improves global clinical function (CIBIC+) compared to placebo across multiple RCTs10,11,17, and a meta-analysis of six RCTs demonstrated significant cognitive improvement at 4 weeks (SMD -0.40, P=0.003) and sustained global clinical benefit at 6 months (OR 4.98)7. In vascular dementia, Cerebrolysin has been reported to produce large improvements in cognitive scores (ADAS-cog+ improvement of 10.6 vs 4.4 points, P<0.0001) and global function (CIBIC+, P<0.0001) versus placebo4. In moderate-to-severe traumatic brain injury, Cerebrolysin appears to improve multidimensional outcome at day 90 compared to placebo (MWcombined 0.59, P=0.012)14. In patients with severe motor impairment after stroke, Cerebrolysin may enhance neuroplastic recovery when combined with standardized rehabilitation13, and may reduce 90-day mortality in patients with severe acute ischemic stroke2.

§05Safety

Cerebrolysin has demonstrated a generally acceptable tolerability profile across a large body of clinical trial data. In a meta-analysis pooling 2,202 patients across 12 RCTs in acute ischemic stroke, no statistically significant differences in adverse event rates were observed between Cerebrolysin and placebo, and at the highest studied dose (50 mL), serious adverse event rates were numerically lower than placebo (RR 0.6)8. The CARS trial reported a premature discontinuation rate below 4%, with no distinguishing safety signals versus placebo12. In Alzheimer's disease trials, adverse event rates were comparable between Cerebrolysin and placebo groups across multiple studies, with one trial reporting 43% versus 38% rates respectively — both within a similar range11. A separate AD trial reported numerically fewer adverse events in the Cerebrolysin arm than placebo (64% vs 73%), with the most common events being headaches, dizziness, weight loss, and anxiety17.

One Cochrane systematic review identified a statistically significant increase in non-fatal serious adverse events at the 30 mL × 10-day cumulative dose in acute ischemic stroke (RR 2.15, 95% CI 1.01–4.55, increasing to RR 2.86 at that specific subgroup)1. Fatal serious adverse event rates were not significantly different from placebo in that analysis1. The combination of Cerebrolysin with alteplase (rt-PA) was explicitly confirmed as safe in a dedicated RCT9. No specific drug interactions or contraindications were identified across the reviewed studies.

§06History

Cerebrolysin was developed in Austria in the 1950s and 1960s by EBEWE Pharma, based on early hypotheses that hydrolyzed brain-derived peptides could support neural repair and cognitive function. The preparation was among the first commercially developed 'nootropic' agents, predating the systematic characterization of neurotrophic factors. It gained regulatory approval and widespread clinical adoption across the Soviet Union, Eastern Europe, and China during the 1970s and 1980s, primarily for stroke, dementia, and traumatic brain injury — indications where no alternative pharmacological treatments were well established.

The modern evidence base began accumulating in the 1990s with the first placebo-controlled RCTs in Alzheimer's disease10, establishing a foundation for clinical validation. Through the 2000s and 2010s, a coordinated series of trials sponsored by Ever Neuro Pharma GmbH (which acquired the Cerebrolysin portfolio) systematically evaluated the drug in acute ischemic stroke2,9,12, Alzheimer's disease3,11,15, vascular dementia4, and traumatic brain injury14. Pooled individual patient data analyses and pre-planned meta-analyses were conducted to consolidate evidence from these trials5,6,7.

Despite this body of work, Cerebrolysin has not received approval from the U.S. Food and Drug Administration or the European Medicines Agency, reflecting regulatory concerns about evidence quality and effect size reliability20. Current research is expanding into aphasia rehabilitation18 and refining patient selection strategies — particularly for severe stroke and TBI phenotypes2,14 — with ongoing efforts to conduct larger, independently funded confirmatory trials.

§07References